🟢 Outlook Therapeutics is trading 10% up today amid biotech-sector strength

Outlook Therapeutics is trading at $0.54, up 10.06%, with biotech-sector strength appearing to be the main context for the October 20 move.

• No fresh company-specific announcement explaining the move was identified.
• The supplied sector data shows XBI up 2.10%; broader biotech sentiment has also been supported by Merck KGaA’s announced acquisition of Silence Therapeutics.
• The broad-market picture is mixed, making biotech the more relevant context.